Veradermics MANE Income Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|
| —— | —— | —— | $28.91M— | ||
| —— | —— | —— | $4.09M— | ||
| —— | —— | —— | $33M— | ||
| —— | —— | —— | -$33M— | ||
| $0-100% | $146.25K— | $292.5K— | $438.75K— | ||
| —— | —— | —— | $732.5K— | ||
| —— | —— | —— | -$32.27M— | ||
| —— | —— | —— | $0— | ||
| —— | —— | —— | -$32.27M— | ||
| —— | —— | —— | -$47.58— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Veradermics profitable?
- Veradermics is not currently profitable: it reported a net loss of $52.9M over the trailing twelve months.
- What is Veradermics 's earnings per share?
- Veradermics 's diluted EPS over the trailing twelve months is $-39.63.
- Where does Veradermics 's income statement data come from?
- Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.